Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Nov 7:43:27-29.
doi: 10.1016/j.jdcr.2023.10.023. eCollection 2024 Jan.

Refractory dermatomyositis responsive to anifrolumab

Phillip S Ang  1 , Ekene Ezenwa  2 , Kichul Ko  3 , Mark D Hoffman  2
Affiliations
Case Reports

Refractory dermatomyositis responsive to anifrolumab

Phillip S Ang et al. JAAD Case Rep. .
No abstract available

Keywords: anifrolumab; antibody; biologic; dermatomyositis; interferon.

PubMed Disclaimer

Conflict of interest statement

None disclosed.

Figures

Fig 1
Fig 1
Dermatomyositis of (A) the face and (B) upper portion of the back at presentation.
Fig 2
Fig 2
(A) Face and (B) upper portion of the back after 5 cycles of intravenous immunoglobulin, and before anifrolumab administration.
Fig 3
Fig 3
Improvement of (A) the face and (B) back following 1 dose of anifrolumab.
Fig 4
Fig 4
Resolution of (A) facial and (B) back activity following 4 doses of anifrolumab.
See this image and copyright information in PMC

References

    1. Cobos G.A., Femia A., Vleugels R.A. Dermatomyositis: an update on diagnosis and treatment. Am J Clin Dermatol. 2020;21(3):339–353. doi: 10.1007/s40257-020-00502-6. - DOI - PubMed
    1. Carter L.M., Wigston Z., Laws P., Vital E.M. Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers. Br J Dermatol. 2023;189(2):210–218. - PubMed
    1. Kalunian K.C., Furie R., Morand E.F., et al. A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus. Arthritis Rheumatol. 2023;75(2):253–265. - PMC - PubMed
    1. Robinson A.B., Reed A.M. Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol. 2011;7(11):664–675. - PubMed
    1. Patil A., Lu J., Kassir M., Babaei M., Goldust M. Adult and juvenile dermatomyositis treatment. J Cosmet Dermatol. 2023;22(2):395–401. doi: 10.1111/jocd.15363. - DOI - PubMed

Publication types

LinkOut - more resources